Immunic Inc. presented Phase 2 trial data for vidofludimus calcium (IMU-838) in treating multiple sclerosis at the ACTRIMS Forum 2024.
Immunic Inc., a biotech company focused on chronic inflammatory and autoimmune diseases, presented data from Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset, vidofludimus calcium (IMU-838), at the ACTRIMS Forum 2024. The poster presentations showcased the strength of the data generated and emphasized the potential of vidofludimus calcium in treating multiple sclerosis.
February 29, 2024
5 Articles